Next-generation humanized patient-derived xenograft mouse model for pre-clinical antibody studies in neuroblastoma
- 11 September 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 70 (3), 721-732
- https://doi.org/10.1007/s00262-020-02713-6
Abstract
Faithful tumor mouse models are fundamental research tools to advance the field of immuno-oncology (IO). This is particularly relevant in diseases with low incidence, as in the case of pediatric malignancies, that rely on pre-clinical therapeutic development. However, conventional syngeneic and genetically engineered mouse models fail to recapitulate the tumor heterogeneity and microenvironmental complexity of human pathology that are essential determinants of cancer-directed immunity. Here, we characterize a novel mouse model that supports human natural killer (NK) cell development and engraftment of neuroblastoma orthotopic patient-derived xenograft (O-PDX) for pre-clinical antibody and cytokine testing. Using cytotoxicity assays, single-cell RNA-sequencing, and multi-color flow cytometry, we demonstrate that NK cells that develop in the humanized mice are fully licensed to execute NK cell cytotoxicity, permit human tumor engraftment, but can be therapeutically redirected to induce antibody-dependent cell-mediated cytotoxicity (ADCC). Although these cells share phenotypic and molecular features with healthy controls, we noted that they lacked an NK cell subset, termed activated NK cells, that is characterized by differentially expressed genes that are induced by cytokine activation. Because this subset of genes is also downregulated in patients with neuroblastoma compared to healthy controls, we hypothesize that this finding could be due to tumor-mediated suppressive effects. Thus, despite its technical complexity, this humanized patient-derived xenograft mouse model could serve as a faithful system for future testing of IO applications and studies of underlying immunologic processes.Funding Information
- National Institutes of Health (CA21765, R50CA211481, EY018599)
- Conquer Cancer Foundation (12822)
- National Institutes of Health (EY014867, CA168875)
- Howard Hughes Medical Institute
This publication has 33 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- The Promise of Patient-Derived Xenografts: The Best Laid Plans of Mice and MenClinical Cancer Research, 2012
- Monocytes derived from humanized neonatal NOD/SCID/IL2Rγnull mice are phenotypically immature and exhibit functional impairmentsHuman Immunology, 2012
- A Functional Role for Tumor Cell Heterogeneity in a Mouse Model of Small Cell Lung CancerCancer Cell, 2011
- Human NK cells of mice with reconstituted human immune system components require preactivation to acquire functional competenceBlood, 2010
- AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3Leukemia, 2010
- Inhibitory KIR–HLA receptor–ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphomaBritish Journal of Cancer, 2007
- Development of a Human Adaptive Immune System in Cord Blood Cell-Transplanted MiceScience, 2004
- Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic TransplantsScience, 2002
- B16 as a Mouse Model for Human MelanomaCurrent Protocols in Immunology, 2000